EXTREME FAT BURNING = Superior Weight Loss with PRO SERIES T3 T4 BOOSTING THERMOGENIC -  this Enhanced Formula Body Fat Burner. EPHALEAN HARDCORE is designed and developed utilising the highest quality Thermogenic ingredients to enhance  & boost FAT BURNING EXCESS WEIGHT LOSS. This Formula which is ideal for both Men & Women is a MAX STRENGTH Solution to your Body Fat Loss requirements. Burn Away the Fat & see the old or New you underneath!

HARDCORE FAT STRIPPER PRO SERIES WEIGHT LOSS TABLETS - maximum potency hardcore fat burners designed to maximise weight loss. A potent combination of tried and tested ingredients in a powerful stacker capsule that can maximise your body weight reduction goals:

LOSE POUNDS
LOSE INCHES
LOSE BODY FAT

• THYROID T3 METABOLISM Booster
• BURN AWAY EXCESS POUNDS & INCHES
• REGULATE BLOOD SUGAR
• LOWER CHOLESTEROL LEVELS
• INCREASE ENERGY LEVELS
• SUPPRESS APPETITE

SERIOUS FAT LOSS FOR MEN & WOMEN - FULL STRENGTH FORMULA

EPHALEAN Hardcore - the ultimate weight loss fat burning stacker tablets for MAXIMUM EXCESS WEIGHT REDUCTION in the shortest space of time. Proven ingredients in a potent stacker capsule for MAXIMUM EFFECT:

HARDCORE EPHALEAN SPECIAL DEAL ORDER NOW only £ 

EXTRA SPECIAL OFFER - 2 BOTTLES FOR THE PRICE OF ONE

FULL STRENGTH MAX POTENCY INGREDIENTS  - designed to strip away excess body fat as well as, increasing T3 thyroid function, and increasing fat-burning activity.. One of the key ingredients is Chromium Polynicotinate which has been shown in research studies to facilitates and/or stimulates the metabolism of sugar, fat and cholesterol in the body, as well as the function of insulin. Major hospital and university studies have suggested that supplementation with chromium will reduce body fat, help build lean body muscle, regulate blood sugar and lower elevated cholesterol. TARRYTOWN, NY -- June 23, 1998 -- Results of a double-blind, placebo controlled clinical study showed that chromium aids in the loss of body fat, without causing a loss in lean body mass. In the study, the 122 moderately overweight individuals who took chromium lost an average of 6.2 pounds of body fat as opposed to only 3.4 pounds in those individuals in the placebo group ~ that's 82% more FAT LOSS!!!!!

Also included in this potent stacker capsule is 5-Hydroxy-L-Tryptophan - 5 HTP in various studies has been shown to boost weight loss and improve sleep patterns. Research suggests that good serotonin levels reduces appetite thereby assisting in weight loss. Serotonin is converted into melatonin in the pineal gland and melatonin, in turn, regulates sleep cycles. As 5 HTP increases serotonin levels it is able to improve sleep and aid in weight loss. 5-HTP can help curb appetite and lead to weight loss. Numerous people have experienced a decrease in appetite from using 5-HTP. 5-HTP helped overweight individuals adhere to dietary recommendations . A twelve week study was divided into two six-week periods. For the first six weeks, there were no dietary recommendations; for the second six weeks the women were placed on a 1,200-calorie diet. As shown in Table 1, the women who took the placebo lost 2.28 pounds, while the women who took the 5-HTP lost 10.34 pounds. 5-HTP appeared to promote weight loss by promoting satiety-the feeling of satisfaction-leading to fewer calories being consumed at meals. Every woman who took the 5-HTP reported early satiety. Another key ingredient is L-Carnitine - L-Carnitine in a study of 18 overweight subjects, carnitine greatly increased weight loss. The subjects were split into two groups of 9. For 12 weeks, both groups ate a healthy diet and performed moderate exercise. One group was given 2000 mg of carnitine, and the other a placebo. In the placebo group, the average weight loss after 12 weeks was one pound. In the carnitine group, weight loss averaged 11 pounds. That’s 11X MORE weight loss, simply by increasing carnitine levels. Body fat percentage levels also decreased markedly in the carnitine group. LOSE EXCESS POUNDS FASTER

Caffeine Anahydrous has been shown to enhance fat-loss, maximize energy, increase performance in aerobic and anaerobic events, and works in synergy with other substances such as l-carnitine

Piper Nigrum has been shown in several clinical studies with healthy volunteers in the U.S to boost gastrointestinal absorption of nutrients, as measured by amounts present in the blood when administered with Piper Nigrum as compared to the control group receiving the nutrient alone. INCREASES THE EFFECTIVENESS OF THE FORMULA


So if you want to LOSE EXCESS BODY FAT FAST then this HARDCORE FORMULATION will help you reach your ideal body shape goals FASTER THAN THROUGH DIET & EXERCISE alone. In fact if you have been dieting and exercising and not getting the results you want then EPHALEAN is just the product you have been looking for!

**WARNING** this is a hardcore formulation designed for use by Adults 18+ only in order to complete the fat loss process you MUST drink at least 3 litres of water every day in order to flush out the fat forming toxins.

So get slimmer & leaner FASTER with HARDCORE EPHALEAN now!!!

THIS IS A FULL STRENGTH FORMULA DESIGNED TO ACCELERATE THE STRIPPING AWAY OF EXCESS LAYERS OF BODY FAT - ONLY USE IF YOU ARE SERIOUS ABOUT FAT LOSS - If you only want to lose a couple of pounds then just this is not for you.

The Science of T3 Fat Loss

Thyroid Hormone or T3 aids in fat loss -  The primary way in which T3 promotes fat loss, is by raising metabolism - T3 predominantly works by increasing levels of uncoupling proteins (UCP's) that uncouple ATP synthesis from mitochondrial oxidation.

The first site of action is obviously UCP1, which leads to an increase in thermogenesis. There are two other UCP's, namely UCP2 and UCP3. UCP2 is most widely expressed, and UCP3 - The role of UCP3 is however not quite clear, as it plays no role in thermogenesis (9), bringing into question whether or not it is really an uncoupling protein. Another method in which T3 increases fat loss is via its metabolite T2. T2 acts directly on the mitochondria to increase their productive ability and thus producing extra ATP.  T2 increases the need for oxygen, so you take up more oxygen which leads to increased cardiovascular pressure to transport all that oxygen to where it is needed (11).

Closely related to the substrate cycling is the effect T3 has on BAR's. During long term stimulation by ligands, such as NE, phosphorylation and deactivation of the B1AR and B2AR can occur, leading to reduced lipolysis in WAT. T3 can increase the expression of BAR's (13) and increase your beta-adrenergic capacity.

T3's effects on insulin and insulin sensitivity - seems to promote adipogenisis, not only via re-esterification of fatty acids, but also through increased sensitivity to insulin (14,15) . It is therefore wise to couple the manipulation of T3 to the manipulation of insulin sensitivity.
However, hyperthyroid states generally lead to a reduction of insulin release (17), due to increased apoptosis of the pancreatic beta-cells (18).

T3 is also a Phosphodiesterase inhibitor (21) since T3 can reduce PDE somewhat, NE down regulates its own negative feedback by increasing T3 levels initially. This same study showed that T3 can prevent Ca2+ dependent proteolysis and possibly spare muscle mass on a diet. This is however highly conflicting information, since T3 is only up regulated at the beginning of a diet, when you are less likely to lose muscle and of course the fact that T3 itself can exert a negative influence on muscle mass retention, since it initiates ubiquitin-proteasome related catabolism (13). T3 also seems to increase Growth Hormone levels (22).

1. Dressel U, Allen TL, Pippal JB, Rohde PR, Lau P, Muscat GE. The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells. Mol Endocrinol. 2003 Dec;17(12):2477-93. Epub 2003 Oct 02.

2. Peters JM, Aoyama T, Burns AM, Gonzalez FJ. Bezafibrate is a dual ligand for PPARalpha and PPARbeta: studies using null mice. Biochim Biophys Acta. 2003 Jun 10;1632(1-3):80-9.

3. Kim MJ, Deplewski D, Ciletti N, Michel S, Reichert U, Rosenfield RL. Limited cooperation between peroxisome proliferator-activated receptors and retinoid X receptor agonists in sebocyte growth and development. Mol Genet Metab. 2001 Nov;74(3):362-9.

4. Axelrod L, Ryan CA, Shaw JL, Kieffer JD, Ausiello DA. Prostacyclin production by isolated rat adipocytes: evidence for cyclic adenosine 3',5'-monophosphate-dependent and independent mechanisms and for a selective effect of insulin. Endocrinology. 1986 Nov;119(5):2233-9.

5. Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T. Prostacyclin-dependent apoptosis mediated by PPAR delta. J Biol Chem. 2001 Dec 7;276(49):46260-7.

6. Rasmusson AM, Southwick SM, Hauger RL, Charney DS. Plasma neuropeptide Y (NPY) increases in humans in response to the alpha 2 antagonist yohimbine. Neuropsychopharmacology. 1998 Jul;19(1):95-8.

7. Sarkar S, Lechan RM. Central administration of neuropeptide Y reduces alpha-melanocyte-stimulating hormone-induced cyclic adenosine 5'-monophosphate response element binding protein (CREB) phosphorylation in pro-thyrotropin-releasing hormone neurons and increases CREB phosphorylation in corticotropin-releasing hormone neurons in the hypothalamic paraventricular nucleus. Endocrinology. 2003 Jan;144(1):281-91.

8. Astrup A, Lundsgaard C, Madsen J, Christensen NJ. Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. Am J Clin Nutr. 1985 Jul;42(1):83-94.

9. Teruel T, Hernandez R, Benito M, Lorenzo M. Rosiglitazone and retinoic acid induce uncoupling protein-1 (UCP-1) in a p38 mitogen-activated protein kinase-dependent manner in fetal primary brown adipocytes. J Biol Chem. 2003 Jan 3;278(1):263-9. Epub 2002 Oct 31.

10. Vidal-Puig A, Solanes G, Grujic D, Flier JS, Lowell BB. UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem Biophys Res Commun. 1997 Jun 9;235(1):79-82.

11. Lanni A, Moreno M, Lombardi A, de Lange P, Goglia F. Control of energy metabolism by iodothyronines. J Endocrinol Invest. 2001 Dec;24(11):897-913.

12. Ma SW, Foster DO. Redox state of brown adipose tissue as a possible determinant of its blood flow. Can J Physiol Pharmacol 62: 949-956, 1984

13. Clement K, Viguerie N, Diehn M, Alizadeh A, Barbe P, Thalamas C, Storey JD, Brown PO, Barsh GS, Langin D. In vivo regulation of human skeletal muscle gene expression by thyroid hormone. Genome Res. 2002 Feb;12(2):281-91.

14. Torrance CJ, Devente JE, Jones JP, Dohm GL. Effects of thyroid hormone on GLUT4 glucose transporter gene expression and NIDDM in rats. Endocrinology. 1997 Mar;138(3):1204-14

15. Romero R, Casanova B, Pulido N, Suarez AI, Rodriguez E, Rovira A. Stimulation of glucose transport by thyroid hormone in 3T3-L1 adipocytes: increased abundance of GLUT1 and GLUT4 glucose transporter proteins. J Endocrinol. 2000 Feb;164(2):187-95.

16. el Hadri K, Pairault J, Feve B. Triiodothyronine regulates beta 3-adrenoceptor expression in 3T3-F442A differentiating adipocytes. Eur J Biochem. 1996 Jul 15;239(2):519-25.

17. Fukuchi M, Shimabukuro M, Shimajiri Y, Oshiro Y, Higa M, Akamine H, Komiya I, Takasu N. Evidence for a deficient pancreatic beta-cell response in a rat model of hyperthyroidism. Life Sci. 2002 Jul 19;71(9):1059-70.

18. Jorns A, Tiedge M, Lenzen S. Thyroxine induces pancreatic beta cell apoptosis in rats. Diabetologia. 2002 Jun;45(6):851-5. Epub 2002 May 17.

19. Viguerie N, Millet L, Avizou S, Vidal H, Larrouy D, Langin D. Regulation of human adipocyte gene expression by thyroid hormone. J Clin Endocrinol Metab. 2002 Feb;87(2):630-4.

20. Richelsen B, Sorensen NS. Alpha 2- and beta-adrenergic receptor binding and action in gluteal adipocytes from patients with hypothyroidism and hyperthyroidism. Metabolism. 1987 Nov;36(11):1031-9.

21. Navegantes LC, Resano NM, Migliorini RH, Kettelhut IC. Catecholamines inhibit Ca(2+)-dependent proteolysis in rat skeletal muscle through beta(2)-adrenoceptors and cAMP. Am J Physiol Endocrinol Metab. 2001 Sep;281(3):E449-54.

22. Volpato CB, Nunes MT. Role of thyroid hormone in the control of growth hormone gene expression. Braz J Med Biol Res. 1994 May;27(5):1269-72.